Association of pNF-H level with survival from time of sample and from time of ALS onset
| Time from sample | Time from onset | ||||
|---|---|---|---|---|---|
| Cohort | pNF-H Sample | HR (95% CI) | p Value | HR (95% CI) | p Value |
| Mayo 12 month (n=20)* | CSF | 1.80 (0.86 to 3.89) | 0.12 | 1.84 (0.81 to 4.27) | 0.14 |
| Serum | 2.10 (1.28 to 3.91) | 0.002 | 1.82 (1.10 to 3.55) | 0.019 | |
| Plasma | 1.87 (1.19 to 3.35) | 0.006 | 1.50 (0.99 to 2.61) | 0.086 | |
| Emory (n=23) | Plasma | 1.48 (1.03 to 2.12) | 0.037 | 1.49 (0.99 to 2.22) | 0.058 |
| Mayo 4 month (n=20) | Plasma | 0.87 (0.53 to 1.36) | 0.54 | 0.87 (0.52 to 1.40) | 0.57 |
| All 3 cohorts (n=62)*† | Plasma | 1.32 (1.07 to 1.64) | 0.012 | 1.18 (0.96 to 1.45) | 0.11 |
*One patient, whose unanticipated death was unrelated to ALS, was censored at the date of death.
†One patient was enrolled in both the Mayo 4 month and Mayo 12 month cohorts; only information from the Mayo 4 month cohort was included in the analysis examining all three cohorts combined.
ALS, amyotrophic lateral sclerosis; pNF-H, phosphorylated neurofilament heavy subunit.
HRs and 95% CI correspond to increased hazard of death or tracheostomy with a doubling of pNF-H.